The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine')
A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine admin...
| Veröffentlicht in: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 2(1980), 5 vom: 08., Seite 330-6 |
|---|---|
| 1. Verfasser: | |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1980
|
| Zugriff auf das übergeordnete Werk: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Schlagworte: | Journal Article Bronchodilator Agents Dihydroergotoxine 11032-41-0 |
| Zusammenfassung: | A study was carried out in 40 patients with bronchial asthma to assess the therapeutic effect of co-dergocrine ('Hydergine'), an alpha-adrenergic receptor blocking agent, when added to their standard treatment with a beta-adrenergic receptor stimulant and aminophylline. Co-dergocrine administration (3 to 6 mg per day) brought about marked improvement in 25% and an improvement in 55% of the patients. The results suggest that co-dergocrine could be a useful drug when combined with other bronchodilators in the treatment of bronchial asthma |
|---|---|
| Beschreibung: | Date Completed 29.01.1981 Date Revised 17.11.2004 published: Print Citation Status MEDLINE |